Market Assessment, Pulmonary Hypertension Pharmacor G7 2014 Report

Pulmonary hypertension (PH) is a devastating disease, for which there is no cure. Despite the rarity of the disease, the potential commercial rewards from drugs approved for it are considerable, driven by the premium price that may be charged for PH agents. Commercial interest in PH has increased thanks to recent and significant advances in the understanding of its etiology and pathophysiology and the emergence of new therapies to treat the disease.

Back to all Market Assessment reports

Contact us

Investors

Careers

Login

Pulmonary Hypertension | Pharmacor | G7 | 2014

Related Market Assessment Reports

Pulmonary Hypertension – Landscape & Forecast – Disease Landscape & Forecast

Pulmonary Hypertension – Current Treatment – Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (US)

Pulmonary Hypertension | Disease Landscape & Forecast | G7 | 2022

Pulmonary Hypertension | Treatment Algorithms: Claims Data Analysis | Pulmonary Arterial Hypertension | US | 2022

Pulmonary Hypertension – Current Treatment – Detailed, Expanded Analysis: Treatment Algorithm Claims Data Analysis-Pulmonary Arterial Hypertension (US)